Поддержание здоровой потери веса с помощью физических упражнений, агониста рецептора GLP-1 или и того, и другого в сочетании с последующим одним годом без лечения: анализ рандомизированного плацебо-контролируемого исследования после лечения
Перевод Г.Е. Заика (08.04.2024)
References
1. Avila C., Holloway A.C., Hahn M.K., et al. An overview of links between obesity and mental health. Curr Obes Rep. 2015;4(3):303–310. [PubMed] [Google Scholar]
2. Kolotkin R.L., Andersen J.R. A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin Obes. 2017;7(5):273–289. [PMC free article] [PubMed] [Google Scholar]
3. Powell-Wiley T.M., Poirier P., Burke L.E., et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):E984–E1010. [PMC free article] [PubMed] [Google Scholar]
4. Narayan K.M.V., Boyle J.P., Thompson T.J., Gregg E.W., Williamson D.F. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007;30(6):1562–1566. [PubMed] [Google Scholar]
5. Friedrichsen M., Breitschaft A., Tadayon S., Wizert A., Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–762. [PMC free article] [PubMed] [Google Scholar]
6. Jensen S.B.K., Janus C., Lundgren J.R., et al. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nat Commun. 2022;13(1):4770. [PMC free article] [PubMed] [Google Scholar]
7. Lundgren J.R., Janus C., Jensen S.B.K., et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–1730. [PubMed] [Google Scholar]
8. Wilding J.P.H., Batterham R.L., Calanna S., et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. [PubMed] [Google Scholar]
9. Jastreboff A.M., Aronne L.J., Ahmad N.N., et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. [PubMed] [Google Scholar]
10. Pi-Sunyer X., Astrup A., Fujioka K., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. [PubMed] [Google Scholar]
11. Rubino D.M., Greenway F.L., Khalid U., et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138. [PMC free article] [PubMed] [Google Scholar]
12. Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. [PMC free article] [PubMed] [Google Scholar]
13. Le Roux C.W., Astrup A., Fujioka K., et al. 3 Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–1409. [PubMed] [Google Scholar]
14. Wharton S., Haase C.L., Kamran E., et al. Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. Obes Sci Pract. 2020;6(4):439. [PMC free article] [PubMed] [Google Scholar]
15. Ganguly R., Tian Y., Kong S.X., et al. Persistence of newer anti-obesity medications in a real-world setting. Diabetes Res Clin Pract. 2018;143:348–356. [PubMed] [Google Scholar]
16. Weiss T., Carr R.D., Pal S., et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337. [PMC free article] [PubMed] [Google Scholar]
17. Weiss T., Yang L., Carr R.D., et al. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care. 2022;10(1):e002517. [PMC free article] [PubMed] [Google Scholar]
18. Rubino D., Abrahamsson N., Davies M., et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. J Am Med Assoc. 2021;325(14):1414–1425. [PMC free article] [PubMed] [Google Scholar]
19. Wilding J.P.H., Batterham R.L., Davies M., et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. [PMC free article] [PubMed] [Google Scholar]
20. Andersen E., Burton N.W., Anderssen S.A. Physical activity levels six months after a randomised controlled physical activity intervention for Pakistani immigrant men living in Norway. Int J Behav Nutr Phys Activ. 2012;9(1):47. [PMC free article] [PubMed] [Google Scholar]
21. Sansano-Nadal O., Giné-Garriga M., Brach J.S., et al. Exercise-based interventions to enhance long-term sustainability of physical activity in older adults: a systematic review and meta-analysis of randomized clinical trials. Int J Environ Res Public Health. 2019;16(14):2527. [PMC free article] [PubMed] [Google Scholar]
22. Skogstad M., Lunde L.K., Ulvestad B., et al. The effect of a leisure time physical activity intervention delivered via a workplace: 15-month follow-up study. Int J Environ Res Public Health. 2018;15(2):1–13. [PMC free article] [PubMed] [Google Scholar]
23. Henderson R.M., Miller M.E., Fielding R.A., et al. Maintenance of physical function 1 Year after exercise intervention in at-risk older adults: follow-up from the LIFE study. J Gerontol A Biol Sci Med Sci. 2018;73(5):688–694. [PMC free article] [PubMed] [Google Scholar]
24. Lindström J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368(9548):1673–1679. [PubMed] [Google Scholar]
25. Jensen S.B.K., Lundgren J.R., Janus C., et al. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. BMJ Open. 2019;9(11):e031431. [PMC free article] [PubMed] [Google Scholar]
26. Jensen S.B.K., Juhl C.R., Janus C., et al. Weight-loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity. 2023;31(4):977–989. [PubMed] [Google Scholar]
27. Sandsdal R.M., Juhl C.R., Jensen S.B.K., et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41. [PMC free article] [PubMed] [Google Scholar]
28. Hays R.D., Sherbourne C.D., Mazel R.M. The rand 36-item health survey 1.0. Health Econ. 1993;2(3):217–227. [PubMed] [Google Scholar]
29. Migueles J.H., Rowlands A.V., Huber F., Sabia S., van Hees V.T. GGIR: a research community–driven open source R package for generating physical activity and sleep outcomes from multi-day raw accelerometer data. J Meas Phys Behav. 2019;2(3):188–196. [Google Scholar]
30. van Hees V.T., Gorzelniak L., Dean León E.C., et al. Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity. PLoS One. 2013;8(4) [PMC free article] [PubMed] [Google Scholar]
31. Van Hees V.T., Fang Z., Langford J., et al. Autocalibration of accelerometer data for free-living physical activity assessment using local gravity and temperature: an evaluation on four continents. J Appl Physiol. 2014;117(7):738–744. [PMC free article] [PubMed] [Google Scholar]
32. Booth M. Assessment of physical activity: an international perspective. Res Q Sport Exerc. 2000;71(Sup 2):114–120. [PubMed] [Google Scholar]
33. Fitzmaurice G., Laird N., Ware J. John Wiley & Sons 2012; 2012. Applied longitudinal analysis. [Google Scholar]
34. James W.P.T., Astrup A., Finer N., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356(9248):2119–2125. [PubMed] [Google Scholar]
35. Smith S.R., Weissman N.J., Anderson C.M., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256. [PubMed] [Google Scholar]
36. Blundell J., Finlayson G., Axelsen M., et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. [PMC free article] [PubMed] [Google Scholar]
37. Maselli D., Atieh J., Clark M.M., et al. Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. Obesity. 2022;30(8):1608–1620. [PMC free article] [PubMed] [Google Scholar]
38. Nicolau J., Pujol A., Tofé S., Bonet A., Gil A. Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity. Physiol Behav. 2022;257 doi: 10.1016/J.PHYSBEH.2022.113967. [PubMed] [CrossRef] [Google Scholar]
39. Barte J.C.M., Ter Bogt N.C.W., Bogers R.P., et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev. 2010;11(12):899–906. [PubMed] [Google Scholar]
40. Quist J.S., Winther J., Friis A.L., et al. Maintenance of cardiorespiratory fitness, body composition, and a physically active lifestyle after structured exercise interventions in individuals with overweight and obesity: a mixed-method follow-up study. Public Health Pract. 2022;4 [PMC free article] [PubMed] [Google Scholar]
41. Murray J.M., Brennan S.F., French D.P., Patterson C.C., Kee F., Hunter R.F. Effectiveness of physical activity interventions in achieving behaviour change maintenance in young and middle aged adults: a systematic review and meta-analysis. Soc Sci Med. 2017;192:125–133. [PubMed] [Google Scholar]